Spearheading a Novel Drug Candidate in Chronic Inflammatory Skin and Joint Diseases
Time: 11:30 am
day: Day 1 AM - Track B
Details:
- Outlining the emerging story of IL-17A and F in inflammatory diseases
- How to Optimize targeting an important cytokine pathway – MOA and unique molecule characteristics of the novel IL-17 drug candidate sonelokimab
- Showcasing disease control by sonelokimab from a phase 2b trial in psoriasis
- Broadening the spectrum – Preparing for success in HS and PsA
